Logo image of BIOS

BIOPLUS ACQUISITION CORP-A (BIOS) Stock Fundamental Analysis

NASDAQ:BIOS - Nasdaq - KYG112171171 - Common Stock - Currency: USD

10.795  -0.01 (-0.05%)

After market: 10.79 -0.01 (-0.05%)

Fundamental Rating

1

Taking everything into account, BIOS scores 1 out of 10 in our fundamental rating. BIOS was compared to 0 industry peers in the Unkown industry. BIOS may be in some trouble as it scores bad on both profitability and health. BIOS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BIOS was profitable.
BIOS had a negative operating cash flow in the past year.
BIOS Yearly Net Income VS EBIT VS OCF VS FCFBIOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2020 2021 2022 0 -100M -200M -300M

1.2 Ratios

Industry RankSector Rank
ROA 4.18%
ROE 4.75%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIOS Yearly ROA, ROE, ROICBIOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2020 2021 2022 0 500 1K 1.5K 2K 2.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BIOS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIOS Yearly Profit, Operating, Gross MarginsBIOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2020 2021 2022 0 20 -20

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for BIOS has been increased compared to 1 year ago.
The debt/assets ratio for BIOS has been reduced compared to a year ago.
BIOS Yearly Shares OutstandingBIOS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2021 2022 20M 40M 60M 80M 100M
BIOS Yearly Total Debt VS Total AssetsBIOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2021 2022 200M 400M 600M

2.2 Solvency

An Altman-Z score of 7.24 indicates that BIOS is not in any danger for bankruptcy at the moment.
BIOS has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 7.24
ROIC/WACCN/A
WACCN/A
BIOS Yearly LT Debt VS Equity VS FCFBIOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2021 2022 0 100M 200M 300M 400M 500M

2.3 Liquidity

A Current Ratio of 0.10 indicates that BIOS may have some problems paying its short term obligations.
BIOS has a Quick Ratio of 0.10. This is a bad value and indicates that BIOS is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.1
Quick Ratio 0.1
BIOS Yearly Current Assets VS Current LiabilitesBIOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2021 2022 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

BIOS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1103.65%, which is quite impressive.
EPS 1Y (TTM)1103.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BIOS Yearly Revenue VS EstimatesBIOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 200M 400M 600M 800M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 53.97 indicates a quite expensive valuation of BIOS.
When comparing the Price/Earnings ratio of BIOS to the average of the S&P500 Index (26.51), we can say BIOS is valued expensively.
Industry RankSector Rank
PE 53.97
Fwd PE N/A
BIOS Price Earnings VS Forward Price EarningsBIOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIOS Per share dataBIOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BIOS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOPLUS ACQUISITION CORP-A

NASDAQ:BIOS (10/6/2023, 8:18:10 PM)

After market: 10.79 -0.01 (-0.05%)

10.795

-0.01 (-0.05%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.55%
Inst Owner Change0%
Ins Owners9.13%
Ins Owner Change0%
Market Cap209.10M
Analysts100
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 53.97
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.72
P/tB 1.72
EV/EBITDA N/A
EPS(TTM)0.2
EY1.85%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0
BVpS6.29
TBVpS6.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.18%
ROE 4.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.1
Quick Ratio 0.1
Altman-Z 7.24
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1103.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-205.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y10.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.39%
OCF growth 3YN/A
OCF growth 5YN/A